AU2020101834A4 - Quercetin compound nanoemulsion based on mongolian medicine sendeng-4 and preparation method therefor - Google Patents
Quercetin compound nanoemulsion based on mongolian medicine sendeng-4 and preparation method therefor Download PDFInfo
- Publication number
- AU2020101834A4 AU2020101834A4 AU2020101834A AU2020101834A AU2020101834A4 AU 2020101834 A4 AU2020101834 A4 AU 2020101834A4 AU 2020101834 A AU2020101834 A AU 2020101834A AU 2020101834 A AU2020101834 A AU 2020101834A AU 2020101834 A4 AU2020101834 A4 AU 2020101834A4
- Authority
- AU
- Australia
- Prior art keywords
- quercetin
- surfactant
- nanoemulsion
- sendeng
- tannin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention belongs to the field of medicine and relates to a quercetin
compound nanoemulsion based on the Mongolian medicine Sendeng-4 and a
5 preparation method for preparing the same. The quercetin compound nanoemulsion
consists of the following raw materials in mass percentage: a surfactant 24.00%~
40.00%, a co-surfactant 0%~20%, oil 3.00%~ 2 3 .5 %, quercetin 0.1976%~0.2056%,
tannin 0.0466%~0.0486%, toosendanin 0.7904%~0.8224%, and distilled water
(remaining amount), a total mass percentage of the above raw materials is 100%. The
10 quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4
prepared by the present invention has good antibacterial effect and good
thermodynamicstability.
1/1
Fig. 1
Fig. 2
Fig. 3
Description
1/1
Fig. 1
Fig. 2
Fig. 3
QUERCETIN COMPOUND NANOEMULSION BASED ON MONGOLIAN MEDICINE SENDENG-4 AND PREPARATION METHOD THEREFOR
Technical Field The present invention belongs to the field of medicine and relates to a new dosage form of an antibacterial drug, in particular to a quercetin compound nanoemulsion based on the Mongolian medicine Sendeng-4 and a method for preparing the same.
Background o Mongolian medicine Sendeng-4 is a commonly used anti-rheumatic medicine in Mongolian medicine. It has efficacies of clearing heat and drydampness, and anti-inflammatory and analgesic, and is used to treat arthritis, edema and other diseases. In recent years, research has found that the Mongolian medicine Sendeng-4 also has a certain effect on the treatment of tinea manus and pedis. The three active ingredients, which are indicators of Sendeng-4 quality control, have certain inhibitory effects on bacteria such as E. coli and Staphylococcus aureus. At present, Sendeng-4 mainly includes soups and capsules on the market, and its nanoemulsion has not been reported. Quercetin, the main component of monarch drug lignum xanthocerais sorbifoliae in Sendeng-4, is poorly water-soluble, and has low bioavailability; and the antibacterial compatibility mechanism between the components is unknown. Therefore, the o development of a compound nanoemulsion with a higher drug loading based on the simplified prescription and components of Sendeng-4 can not only improve the efficacy, but also explain the compatibility mechanism of the main components in Mongolian medicine Sendeng-4.
Summary In view of the above problems and defects in the current technology, the object of the present invention is to provide a quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 with good solubility, stable properties, high bioavailability and good antibacterial effect and a method for preparing the same. The object of the present is realized by the following technical schemes: A quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4, consisting of the following raw materials in mass percentage: a surfactant 24.00%~40.00%, a co-surfactant
0%~20%, oil 3.00%~23.5%, quercetin 0.1976%~0.2056%, tannin 0.0466%~0.0486%, toosendanin 0.7904%~0.8224%, the rest being distilled water, and a total mass percentage of the above raw materials is 100%. Further, for the selection of surfactants, the present invention selects non-toxic and biocompatible non-ionic surfactants. The non-ionic surfactants are relatively stable in solution and are not affected by strong electrolytes and inorganic salts, also not affected by strong bases, and have good compatibility with other surfactants. The present invention selects a nonionic surfactant with an HLB of 10 to 15, which may be selected from one or a mixture of several of Tween-80 (polysorbate-80), RH-40 (polyoxyethylene hydrogenated castor oil), EL-40 (castor oil polyoxyethylene ether) and emulsifier OP-10. o Further, the present invention is based on the principle that the emulsion formed is stable when the HLB of the surfactant required to emulsify the oil phase is close to that of the surfactant, and the selected oil is any one or a mixture of several of ethyl acetate, glyceryl triacetate, and isopropyl myristate. Further, the co-surfactant is any one or a mixture of several of absolute ethanol, isopropyl alcohol, and 1,2-propylene glycol. Further, the particle size of the nanoemulsion is 1 to 100 nm. Further, the nanoemulsion further comprises geniposide at a mass percentage of 0.1784% to 0.1804%. The main chemical component of the gardenin is iridoid, which has a significant anti-inflammatory effect and may enhance the anti-inflammatory effect of the nanoemulsion. o Further, the nanoemulsion consists of the following raw materials in mass percentage: a surfactant 25%, a co-surfactant 12.5%, oil 4 .4 %, quercetin 0.2016%, tannin 0.0476%, toosendanin 0.8064%, and distilled water (remaining amount), and a total mass percentage of the above raw materials is 100%. Further, the nanoemulsion consists of the following raw materials in mass percentage: a surfactant 2 5 %, a co-surfactant 1 2 .5 %, oil 4.4%, quercetin 0. 2 0 16%, tannin 0.0 4 7 6 %, geniposide 0.1794%, toosendanin 0.8064%, and distilled water (remaining amount), a total mass percentage of the above raw materials is 100%. Further, the nanoemulsion consists of the following raw materials in mass percentage: Tween-80 25 .0%, absolute ethanol 1 2 .5 %, 4 .4 %, ethyl acetate quercetin 0. 2 0 16%, tannin 0.0 4 7 6 %, geniposide 0.1794%, toosendanin 0.8064%, and distilled water (remaining amount), a total mass percentage of the above raw materials is 100%. A method for preparing a quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4, comprising the following steps:
Step 1, weighing a surfactant, oil, a co-surfactant, quercetin, tannin, tamarind and distilled water according to a formula proportion for use; Step 2, dissolving the quercetin and tamarind in oil to obtain a mixture, and heating the mixture to 40-60°C as an oil phase; Step 3, adding the surfactant to the oil phase and stirring to mix well; Step 4, adding the co-surfactant to a mixture of the oil phase and the surfactant, and stirring to mix well; Step 5, adding the tannin to distilled water to obtain a mixture, which is heated to 40-60°C and mixed well as an aqueous phase; o Step 6, stirring a mixture of the oil phase, the surfactant and the co-surfactant while adding the water phase dropwise, and continuing stirring until the mixture is a transparent liquid to obtain the compound quercetin antibacterial nanoemulsion. Further, when the nanoemulsion raw material comprises geniposide, in step 5, adding the geniposide and the weighed according to a formula proportion together in distilled water, heating the distilled water containing the geiposide and mixing well as an aqueous phase. Further, in step 3, a stirring time is 30 minutes, and a stirring speed is 800 rpm/min; and in step 4, a stirring time is 15 minutes, and a stirring speed is 800 rpm/min. Compared with the prior art, the quercetin compound nanoemulsion antibacterial drug based on Mongolian medicine Sendeng-4 of the present invention has the following advantages: o (1) The quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 of the present invention has good antibacterial effect. (2) The quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 of the present invention is of the O/W type (oil-in-water type), with good thermodynamic stability. It has a droplet size of 1-100 nm, good fluidity, no layering, no precipitation, and high storage stability. (3) The quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 of the present invention is evenly distributed, clear and transparent, and may be infinitely diluted in water and absorbed well. (4) The preparation method for the quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 of the present invention has a good solubilization effect, greatly increasing the solubility of quercetin and tannin, thereby enhancing the antibacterial properties of the nanoemulsion.
(5) The preparation method for the quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 of the present invention is simple and safe.
Brief Description Of Drawings Figure 1 is plate results of the antibacterial test of quercetin nanoemulsion, quercetin + tannin nanoemulsion, quercetin + tannin + toosendanin nanoemulsion, quercetin + tannin + toosendanin + geniposide nanoemulsion against Pseudomonas aeruginosa; Figure 2 is plate results of the antibacterial test of quercetin nanoemulsion, quercetin + tannin nanoemulsion, quercetin + tannin + toosendanin nanoemulsion, quercetin + tannin + toosendanin o + geniposide nanoemulsion against Escherichia coli; Figure 3 is plate results of the antibacterial test of quercetin nanoemulsion, quercetin + tannin nanoemulsion, quercetin + tannin + toosendanin nanoemulsion, quercetin + tannin + toosendanin + geniposide nanoemulsion against Staphylococcus aureus;
Detailed Description In order that the objectives, technical schemes and advantages of the present invention will become more apparent, the present invention will be described in more detail with reference to the drawings and examples above. It should be understood that the specific embodiments described herein are only for illustrating but not for limiting the present invention.
Example 1 A quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4. The nanoemulsion has a particle size of 1-100 nm, consisting of the following raw materials in mass percentage: Tween-80 25.0%, ethyl acetate 4.4%, absolute ethanol 12.5%, quercetin 0.2016%, tannin 0.0476%, toosendanin 0.8064%, and distilled water (remaining amount), and a total mass percentage of the above raw materials is 100%. The above method for preparing a quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4, comprising the following steps: Step 1, weighing Tween-80, ethyl acetate, absolute ethanol, quercetin, tannin, tamarind and distilled water according to a formula proportion for use; Step 2, dissolving the quercetin and tamarind in ethyl acetate, and heating the ethyl acetate containing quercetin and tamarind to 40-60°C to fully dissolve it as an oil phase; Step 3, adding Tween-80 to the oil phase, and stirring at 800 rpm/min for 30 minutes to mix well;
Step 4, adding absolute ethanol to a mixture of the oil phase and the surfactant, and stirring at 800 rpm/min for 15 minutes to mix well; Step 5, adding the tannin to distilled water to obtain a mixture, which is heated to 40-60°C and mixed well as an aqueous phase; Step 6, stirring a mixture of the oil phase, the surfactant and the co-surfactant quickly, meanwhile adding the water phase dropwise slowly, and continuing stirring until the mixture is a transparent liquid to obtain the Mongolian medicine compound quercetin antibacterial nanoemulsion.
Example 2 o A quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4, and the mass percentage of each component is: RH-40 27%, isopropyl myristate 3.3%, absolute ethanol 1%, quercetin 0.2%, tannin 0.0486%, geniposide 0.18%, toosendanin 0.8%, and distilled water (remaining amount).
Example 3 A quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4, and the mass percentage of each component is: EL-40 36%, absolute ethanol 12%, ethyl acetate 4%, quercetin 0.2%, tannin 0.0475%, geniposide 0.18%, toosendanin 0.8224%, and distilled water (remaining amount).
Example 4 o A quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4, and the mass percentage of each component is: Tween-80 27%, ethyl acetate 4.4%, 1,2-propanediol 13.5%, quercetin 0.2%, tannin 0.0486%, geniposide 0.18%, toosendanin 0.8%, and distilled water (remaining amount).
Example 5 A quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4, and the mass percentage of each component is: Tween-80 30%, ethyl acetate 4.0%, isopropyl alcohol 10.5%, quercetin 0.1976%, tannin 0.0486%, toosendanin 0.7904%, and distilled water (remaining amount).
Example 6 A quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4, and the mass percentage of each component is: Tween-80 30%, isopropyl myristate 3.0%, absolute ethanol 5%, quercetin 0.2050%, tannin 0.0476%, toosendanin 0.8%, and distilled water (remaining amount).
Example 7 The antibacterial effect of the quercetin compound nanoemulsion based on the Mongolian medicine Sendeng-4 was tested by the following test: (1) The tested sample was a nanoemulsion of one or a mixture of several of quercetin, tannin, toosendanin and geniposide. (2) Strains: Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa. (3) Medium: nutrient broth medium, nutrient broth agar medium. o (4) Steps of the antibacterial experiment method: 1) Preparing required culture medium according to the formula and sterilizing for use; 2) activating the required strains; 3) adjusting the activated strains to 0.5 McFarland standard; 4) diluting each antibacterial agent of the present invention to the required concentration, adding it to a test tube of liquid culture medium, and mixing well for use (multiple dilution method); 5) adding 105 cfu/ml of experimental bacterial suspension to the prepared drug-containing medium in step 4); 6) after the above step 5) was completed, culturing the test tube at room temperature for 18-24h, and the concentration of aseptic growth observed with the naked eye was the minimum o inhibitory concentration. 7) Obtaining the respective MIC of each tested sample, combining three kinds of nanoemulsions of tannin nanoemulsion, geniposide nanoemulsion, and toosendanin nanoemulsion with quercetin nanoemulsion, respectively, and then adding 50[ 1of each 2MIC mass concentration of tannin nanoemulsion, gardenoside nanoemulsion and toosendanin nanoemulsion to the microwells, wherein the tannin nanoemulsion, geniposide nanoemulsion, or toosendanin nanoemulsion were arranged in a row, and the mixture of tannin nanoemulsion, geniposide nanoemulsion or toosendanin nanoemulsion and quercetin nanoemulsion was arranged in a column; 8) adding the activated bacterial suspension in step 2), making the bacterial concentration 10 5 cfu and mixing well; placing the mixture in a microplate reader quickly and measuring the optical density (OD) of each culture well at a wavelength of 600nm; incubating the mixture at 37C for 18-24h, shaking it well, and placing it in the microplate reader again to measure the OD of each culture well; the antibacterial OD of the tested drug = OD after cultivation-GD before cultivation. the smaller the OD difference, the less bacteria, and the strongest antibacterial activity of the drug. The best combination of the two drugs was recorded and the combined MIC was obtained; FIC index = MIC for combined use of A drug/MIC for single use of A drug + MIC for combined use of B drug/MIC for single use of B drug FIC index <0.5 synergistic effect, FIC index>0.5-1 additive effect, FIC index>1-2 irrelevant effect, FIC index>2 antagonistic effect; o According to the optimal concentration of the combination of the two tested samples obtained above, four drug-containing nanoemulsions quercetin, quercetin + tannin, quercetin + tannin
+ toosendanin, quercetin + tannin + toosendanin + geniposide were prepared respectively. The test method was the same as the double dilution method in.step 4), in which the drugs were successively diluted multiple times, and marked as (1@ @ @ @ @ respectively. The
antibacterial efficacy of the four drug-containing nanoemulsions was compared. The concentration of aseptic growth observed with the naked eye was the minimum inhibitory concentration. All the liquid in the test tubes with sterile growth visible to the naked eye was shaken well and plated. (5) Test results Table 1 MIC of nanoemulsion containing four active ingredients of quercetin, tannin, toosendanin and geniposide (mg/ml) Strain quercetin tannin geniposide toosendanin Drug nanoemulsion nanoemulsion nanoemulsion nanoemulsion
Staphylococcus 1.024 0.032 1.024 16.384 aureus Escherichia coli 2.048 2.048 4.096 8.912 Pseudomonas 0.512 0.512 1.024 32.768 aeruginosa
Table 2 MIC of single-use quercetin nanoemulsion/tannin nanoemulsion and FIC of combined quercetin nanoemulsion/tannin nanoemulsion Strain single combined FIC interaction MIC medication MIC medication MIC
Staphylococcus 1.024/0.032 0.064/0.004 0.0938 synergy aureus Pseudomonas 0.512/0.512 0.008/0.128 0.2656 synergy aeruginosa
Table 3 MIC of single-use quercetin nanoemulsion/toosendanin nanoemulsion and FIC of combined quercetin nanoemulsion/tannin nanoemulsion Strain single combined FIC interaction MIC medication MIC medication MIC
Staphylococcus 1.024/16.384 0.064/0.256 0.0781 synergy aureus Pseudomonas 0.512/32.768 0.128/1.024 0.2813 synergy aeruginosa
Table 4 MIC of single-use quercetin nanoemulsion/geniposide nanoemulsion and FIC of combined quercetin nanoemulsion/tannin nanoemulsion Strain single combined FIC interaction MIC medication MIC medication MIC
Staphylococcus 1.024/1.024 2.048/2.048 4 antagonism aureus Pseudomonas 0.512/1.024 1.024/0.032 2.0313 antagonism aeruginosa Through the combined antibacterial experiment of tannin, toosendanin, geniposide and quercetin, it can be concluded that: the combination of quercetin and tannin shows a synergistic effect, and the MIC of Staphylococcus aureus when combined is 1/16 and 1/8 times when used alone, and the MIC of Pseudomonas aeruginosa is 1/64 and 1/4 times when used alone, the combination of quercetin and tazelin shows a synergistic effect, and the MIC of Staphylococcus aureus when combined is 1/16 and 1/64 times when used alone, and the MIC of Pseudomonas aeruginosa is 1/4 and 1/32 times when used alone; and the combination of quercetin and geniposide shows an antagonistic effect. Figures 1 to 3 are referred to, which are the results of the antibacterial tests of four drug-containing nanoemulsions quercetin, quercetin + tannin, quercetin + tannin + toosendanin, quercetin + tannin + toosendanin + geniposide against Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus, respectively, wherein a, b, c, d in Figure 1, e, f, g, h in Figure 2 and i, j, k, and 1 in Figure 3 are four drug-containing nanoemulsions quercetin, quercetin + tannin, quercetin + tannin + toosendanin, quercetin + tannin + toosendanin + geniposide, respectively. The results are as follows:
Table 5 antibacterial test results of four drug-containing nanoemulsions quercetin, quercetin + tannin, quercetin + tannin + toosendanin, quercetin + tannin + toosendanin + geniposide against Pseudomonas aeruginosa Drug @ @@ quercetin nanoemulsion - - ++ ++++++ quercetin + tannin nanoemulsion - - ++++ ++++++ quercetin + tannin + toosendanin - - - +++++ nanoemulsion quercetin + tannin + toosendanin + + ++ +++ ++++++ geniposide nanoemulsion
Table 6 antibacterial test results of four drug-containing nanoemulsions quercetin, quercetin + tannin, quercetin + tannin + toosendanin, quercetin + tannin + toosendanin + geniposide against Escherichia coli Drug ( @ quercetin nanoemulsion - ++++++ ++++++ quercetin + tannin nanoemulsion - ++++++ ++++++ quercetin + tannin + toosendanin - - ++++++ nanoemulsion quercetin + tannin + toosendanin + + ++ ++++++ geniposide nanoemulsion
Table 7 antibacterial test results of triple drug-containing nanoemulsions quercetin, quercetin + tannin, quercetin + tannin + toosendanin, quercetin + tannin + toosendanin + geniposide against Staphylococcus aureus Drug quercetin nanoemulsion - ++++ ++++ ++++++
quercetin + tannin nanoemulsion - ++ ++ ++++++ quercetin + tannin + toosendanin - - - ++ nanoemulsion quercetin + tannin + toosendanin + - ++ ++++ ++++++ geniposide nanoemulsion ++ Note:- no bacterial growth, + 1 colony, ++ 2 colonies, +++3 colonies, +++++ 4 colonies, ++ ++++ 5 colonies, ++++++ colonies number is greater than 5
By comparing the antimicrobial properties of quercetin, quercetin + tannin, quercetin + tannin
+ toosendanin, quercetin + tannin + toosendanin + geniposide with the double dilution method, it can be concluded that: quercetin + tannin + toosendanin nanoemulsion> quercetin + tannin nanoemulsion> quercetin nanoemulsion> quercetin + tannin + toosendanin + geniposide nanoemulsion. It shows that the combination of quercetin + tannin + toosendanin nanoemulsion has the strongest antibacterial properties. Example 8 The appearance of the nanoemulsion prepared in the above example was a pale yellow transparent liquid. The nanoemulsion had a particle size of 1-100 nm determined by the transmission electron microscopy, and has good stability. The stability test was as follows: (1) Accelerated stability: the Mongolian medicine compound nanoemulsion was placed in a 1Oml centrifuge tube and centrifuged at 12000 rpm/min for 20 min. The appearance of the nanoemulsion was clear and transparent, and there was no delamination or demulsification. (2) Thermal storage stability: the Mongolian medicine compound nanoemulsion was placed in a vial, sealed, and stored in a 40°C incubator for 3 months. The appearance of the nanoemulsion was clear and transparent, and there was no delamination or demulsification.
(3) Anti-freezing stability: the Mongolian medicine compound nanoemulsion was stored at -4C.
The appearance of the nanoemulsion was still clear and transparent at 0, 5, and 10 days, the liquid was uniform, and there was no delamination or demulsification. (4) Light stability: the Mongolian medicine compound nanoemulsion was observed under (4500±500) lx conditions on 0, 5, and 10 days. The appearance of the nanoemulsion was clear and transparent, and there was no delamination or demulsification. The foregoing is merely illustrative of the preferred embodiments of the present invention and is not intended to be limiting of the present invention, and for those skilled in the art, the present invention may have various changes and modifications. Any modifications, equivalent substitutions, improvements, and the like within the spirit and principles of the invention are intended to be included within the scope of the present invention.
Claims (10)
1. A quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4, consisting of the following raw materials in mass percentage: a surfactant 24.00%~40.00%, a co-surfactant
%~20%, oil 3.00%~23.5%, quercetin 0.1976%~0.2056%, tannin 0.0466%~0.0486%,
toosendanin 0.7904%~0.8224%, and distilled water (remaining amount), and a total mass
percentage of the above raw materials being 100%.
2. The quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 according to claim 1, wherein the surfactant is a nonionic surfactant with an HLB value of 10-15.
3. The quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 according to claim 1, wherein the surfactant is any one or a mixture of several of Tween-80, RH-40, EL-40, and emulsifier OP-10; the oil is any one or a mixture of several of ethyl acetate, glyceryl triacetate, and isopropyl myristate; the co-surfactant is any one or a mixture of several of absolute ethanol, isopropyl alcohol, and 1,2-propylene glycol.
4. The quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 according to claim 1, wherein the nanoemulsion has a particle size of 1-100 nm.
5.The quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 according to claim 1, wherein the quercetin compound nanoemulsion further comprises geniposide at a mass percentage of 0.1784%~0.1804%.
6. The quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 according to claim 1, consisting of the following raw materials in mass percentage: a surfactant 25%, a co-surfactant 1 2 .5 %, oil 4 .4 %, quercetin 0. 2 0 16%, tannin 0.04 7 6 %, toosendanin 0. 8 0 6 4 %, and distilled water (remaining amount), and a total mass percentage of the above raw materials being 100%.
7. The quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 according to claim 5, consisting of the following raw materials in mass percentage: a surfactant 25%, a co-surfactant 12.5%, oil 4.4%, quercetin 0.2016%, tannin 0.0476%, toosendanin 0.8064%, geniposide 0.1794%, and distilled water (remaining amount), and a total mass percentage of the above raw materials being 100%.
8. A method for preparing a quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4, comprising the following steps: Step 1, weighing a surfactant, oil, a co-surfactant, quercetin, tannin, tamarind and distilled water according to a formula proportion for use; Step 2, dissolving the quercetin and tamarind in the oil, and heating the oil containing quercetin and tamarind to 40-60°C as an oil phase; Step 3, adding the surfactant to the oil phase, and stirring to mix well; Step 4, adding the co-surfactant to a mixture of the oil phase and the surfactant, and stirring to mix well; Step 5, adding the tannin to distilled water, heating the distilled water containing the tannin to -60°C and mixing well as an aqueous phase; Step 6, stirring a mixture of the oil phase, the surfactant and the co-surfactant, meanwhile adding the water phase dropwise, and continuing stirring until the mixture is a transparent liquid to obtain the compound quercetin antibacterial nanoemulsion.
9. The method for preparing a quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 according to claim 8, wherein when the nanoemulsion raw material comprises geniposide, in step 5, adding the geniposide and the weighed according to a formula proportion together in distilled water, heating the distilled water containing the geiposide and mixing well as an aqueous phase.
10. The method for preparing a quercetin compound nanoemulsion based on Mongolian medicine Sendeng-4 according to claim 8, wherein in step 3, a stirring time is 30 minutes, and a stirring speed is 800 rpm/min; and in step 4, a stirring time is 15 minutes, and a stirring speed is 800 rpm/min.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010308277.6 | 2020-04-18 | ||
| CN202010308277.6A CN111544387B (en) | 2020-04-18 | 2020-04-18 | Compound quercetin antibacterial nanoemulsion and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020101834A4 true AU2020101834A4 (en) | 2020-09-24 |
Family
ID=71996323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020101834A Ceased AU2020101834A4 (en) | 2020-04-18 | 2020-08-14 | Quercetin compound nanoemulsion based on mongolian medicine sendeng-4 and preparation method therefor |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN111544387B (en) |
| AU (1) | AU2020101834A4 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114522139A (en) * | 2022-01-28 | 2022-05-24 | 深圳玉莱漫生物科技有限公司 | Herbal anti-inflammatory transdermal absorption microemulsion gel and preparation method thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112843047A (en) * | 2021-03-31 | 2021-05-28 | 重庆市公共卫生医疗救治中心 | Application of quercetin in enhancing bactericidal ability of antibacterial drugs |
| CN113712988A (en) * | 2021-08-17 | 2021-11-30 | 塔里木大学 | Quercetin-tilmicosin polymer nanoparticles as well as preparation method and application thereof |
| CN114404325A (en) * | 2022-01-13 | 2022-04-29 | 上海应用技术大学 | Oil-in-water rapeseed oil microemulsion capable of being infinitely diluted, and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080274195A1 (en) * | 2005-07-18 | 2008-11-06 | University Of Massachusetts Lowell | Compositions and Methods for Making and Using Nanoemulsions |
| CN105534897A (en) * | 2015-12-27 | 2016-05-04 | 常州亚环环保科技有限公司 | Preparation method of highly water-soluble quercetin microemulsion |
| CN108271794A (en) * | 2018-02-06 | 2018-07-13 | 浦江县美泽生物科技有限公司 | A kind of margosine method for producing insecticide |
| CN110037986B (en) * | 2019-06-06 | 2021-11-16 | 内蒙古自治区国际蒙医医院(内蒙古自治区蒙医药研究所) | Senden-4 nanoemulsion and preparation method thereof |
-
2020
- 2020-04-18 CN CN202010308277.6A patent/CN111544387B/en not_active Expired - Fee Related
- 2020-08-14 AU AU2020101834A patent/AU2020101834A4/en not_active Ceased
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114522139A (en) * | 2022-01-28 | 2022-05-24 | 深圳玉莱漫生物科技有限公司 | Herbal anti-inflammatory transdermal absorption microemulsion gel and preparation method thereof |
| CN114522139B (en) * | 2022-01-28 | 2023-09-15 | 深圳玉莱漫生物科技有限公司 | Herbal anti-inflammatory transdermal absorption microemulsion gel and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111544387A (en) | 2020-08-18 |
| CN111544387B (en) | 2021-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020101834A4 (en) | Quercetin compound nanoemulsion based on mongolian medicine sendeng-4 and preparation method therefor | |
| Khezri et al. | Accelerated infected wound healing by topical application of encapsulated Rosemary essential oil into nanostructured lipid carriers | |
| Letsididi et al. | Antimicrobial and antibiofilm effects of trans-cinnamic acid nanoemulsion and its potential application on lettuce | |
| Cui et al. | The specific antibacterial activity of liposome-encapsulated Clove oil and its application in tofu | |
| Prateeksha et al. | Nanoemulsion-loaded hydrogel coatings for inhibition of bacterial virulence and biofilm formation on solid surfaces | |
| Rossi et al. | Antibiofilm activity of nanoemulsions of Cymbopogon flexuosus against rapidly growing mycobacteria | |
| CN103860547B (en) | A kind of herbal composite antimicrobial nano breast and preparation method thereof | |
| CN110898008A (en) | Nano-antibacterial emulsion containing tea tree essential oil and preparation method thereof | |
| WO2022199653A1 (en) | Method for preparing eucalyptol emulsion and application thereof in biopesticide | |
| Gandhi et al. | Development and characterization of microemulsion based topical gel of essential oil of clove (Syzygium aromaticum) for superficial fungal infections | |
| CN109820823A (en) | A kind of preparation method and applications of hypochlorous acid micro emulsion | |
| Zaharia et al. | Bioactive emulsions with beneficial antimicrobial application in textile material production | |
| Hasanvand et al. | A comparative study on antibacterial activity of carvacrol and glutaraldehyde on Pseudomonas aeruginosa and Staphylococcus aureus isolates: an in vitro study | |
| CN102228432A (en) | Ofloxacin nanoemulsion antibacterial medicine and preparation method thereof | |
| TW202406577A (en) | The ointment of rifamycin-quinolizidone conjugate molecule and preparation thereof | |
| CN115364091B (en) | Ophthalmic preparation of artemisinin derivative and preparation method thereof | |
| Younis et al. | Standardization and quantitative analysis of Araucaria Heterophylla extract via an UPLC-MS/MS method and its formulation as an antibacterial phytonanoemulsion gel | |
| CN101756899A (en) | Valnemulin nano-emulsion antibacterial medicine preparation | |
| Sultana et al. | Antibacterial effect of aqueous neem (Azadirachta indica) leaf extract, crude neem leaf paste, and ceftriaxone against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa | |
| Han et al. | Preparation of tea tree oil nanoemulsion: Characterisation, antibacterial mechanism and evaluation of apoptosis | |
| PAPAYA | OPTIMIZATION OF CARBOPOL 940 AND PROPYLENE GLYCOL CONCENTRATION ON THE CHARACTERISTIC AND INHIBITORY EFFECT OF ETHANOL EXTRACT GEL OF PAPAYA (Carica papaya L.) SEEDS AGAINST Staphylococcus aureus Octavianus Yandri, Wahyuning Setyani | |
| CN109431999B (en) | Nano self-microemulsion, veterinary drug nano self-microemulsion and preparation method and application thereof | |
| Putta et al. | Development, systematic optimisation and biofilm disruption activity of eugenol-based nanosized emulsions stabilised with Tween 80 | |
| CN102274228B (en) | Compound trimethoprim and sodium succinate florfenicol nanoemulsion preparation and preparation thereof | |
| Gandhi et al. | Design, fabrication and evaluation of microemulsion based gel of essential oil of thymus vulgaris for superficial fungal infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: INNER MONGOLIA AUTONOMOUS REGION INTERNATIONAL MONGOLIAN MEDICINE HOSPITAL (INNER MONGOLIA AUTONOMOUS REGION MONGOLIAN MEDICINE RESEARCH INSTITUTE) Free format text: FORMER NAME(S): INNER MONGOLIA AUTONOMOUS REGION INTERNATIONAL MONGOLIAN MEDICINE HOSPITAL; INNER MONGOLIA MEDICAL UNIVERSITY Owner name: INNER MONGOLIA MEDICAL UNIVERSITY Free format text: FORMER NAME(S): INNER MONGOLIA AUTONOMOUS REGION INTERNATIONAL MONGOLIAN MEDICINE HOSPITAL; INNER MONGOLIA MEDICAL UNIVERSITY |
|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |